These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9076577)

  • 1. Evidence for both abnormal set point of PTH stimulation by calcium and adaptation to serum calcium in hemodialysis patients with hyperparathyroidism.
    Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Rodriguez AP; Felsenfeld AJ
    J Bone Miner Res; 1997 Mar; 12(3):347-55. PubMed ID: 9076577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients.
    Brossard JH; Roy L; Lepage R; Gascon-Barré M; D'Amour P
    Miner Electrolyte Metab; 1997; 23(1):25-32. PubMed ID: 9058366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
    Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
    Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
    Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol.
    Malberti F; Surian M; Cosci P
    Kidney Int Suppl; 1993 Jun; 41():S125-30. PubMed ID: 8320905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism.
    Malberti F; Surian M; Cosci P
    Nephrol Dial Transplant; 1992; 7(8):822-8. PubMed ID: 1325615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism.
    Caravaca F; Cubero JJ; Jimenez F; López JM; Aparicio A; Cid MC; Pizarro JL; Liso J; Santos I
    Nephrol Dial Transplant; 1995; 10(5):665-70. PubMed ID: 7566580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Low dosage intravenous calcitriol bolus therapy in chronic hemodialysis patients].
    Neyer U; Wöss E; Drexel H
    Acta Med Austriaca; 1994; 21(5):129-32. PubMed ID: 7709710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient.
    Rodriguez M; Caravaca F; Fernandez E; Borrego MJ; Lorenzo V; Cubero J; Martin-Malo A; Betriu A; Jimenez A; Torres A; Felsenfeld AJ
    Kidney Int; 1999 Jul; 56(1):306-17. PubMed ID: 10411707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve.
    Bas S; Aguilera-Tejero E; Bas A; Estepa JC; Lopez I; Madueño JA; Rodriguez M
    J Endocrinol; 2005 Jan; 184(1):241-7. PubMed ID: 15642800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo studies of parathyroid gland function in secondary hyperparathyroidism.
    Salusky IB; Goodman WG
    Adv Nephrol Necker Hosp; 1996; 25():289-302. PubMed ID: 8717632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
    Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
    Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
    Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iatrogenic hypercalcemia in hemodialysis patients.
    Muhammedi MA; Piraino B; Rault R; Johnston JR; Puschett JB
    Clin Nephrol; 1991 Nov; 36(5):258-61. PubMed ID: 1752077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dependency of calcium set point on basal plasma calcium in dialysis patients: a better explanation for the discrepancies regarding its link with PTH secretion than methodological differences.
    Hardy-Yverneau P; Shenouda M; Moriniere P; Legallais C; Brazier M; Achard J; Fournier A
    Clin Nephrol; 1998 Oct; 50(4):236-46. PubMed ID: 9799069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
    Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
    Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.